XHXiang-Hu He

Xiang-Hu He

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Xiang-Hu He has a total of 39 co-authors. Here are the top co-authors by number of shared publications:

  • Xuetao Yan

    Department of Anesthesiology, Bao'an Maternal and Child Health Hospital, Jinan University, Shenzhen, China

    5 shared publications
  • Meng Chen

    Department of Anesthesiology, Zhongnan Hospital of Wuhan University, Wuhan, China

    4 shared publications
  • Xue-Tao Yan

    Department of Anesthesiology, Shenzhen Bao'an Maternity and Child Health Hospital, China

    4 shared publications
  • Zong-Ze Zhang

    Department of Anesthesiology, Zhongnan Hospital of Wuhan University, Hubei, China

    4 shared publications
  • Hu Chen

    Department of Anesthesiology, Bao'an Maternal and Child Health Hospital, Jinan University, Shenzhen, China

    3 shared publications
  • Tuo Ji

    Department of Anesthesiology, School and Hospital of Stomatology, Wuhan University, Wuhan, China

    3 shared publications

Latest Publications

  • Open Access

    Emodin alleviates intestinal ischemia–reperfusion injury through antioxidant stress, anti-inflammatory responses and anti-apoptosis effects via Akt-mediated HO-1 upregulation

    by Yinyin Liu, Tuo Ji, Haixing Jiang, Meng Chen, Wanli Liu, Zongze Zhang, Xianghu He

    Background: Intestinal ischemia–reperfusion (I/R) injury is a severe vascular emergency. Previous research indicated the protective effects of Emodin on I/R injury. Our study aims to explore the effect of Emodin on intestinal I/R (II/R) injury and elucidate the underlying mechanisms.Methods: C57BL/6 mice and Caco-2 cells were used for in vivo and in vitro studies. We established an animal model of II/R injury by temporarily occluding superior mesenteric artery. We constructed an oxygen–glucose deprivation/reoxygenation (OGD/R) cell model using a hypoxia-reoxygenation incubator. Different doses of Emodin were explored to determine the optimal therapeutic dose. Additionally, inhibitors targeting the protein kinase B (Akt) or Heme oxygenase-1 (HO-1) were administered to investigate their potential protective mechanisms.Results: Our results demonstrated that in animal experiments, Emodin mitigated barrier disruption, minimized inflammation, reduced oxidative stress, and inhibited apoptosis. When Akt or HO-1 was inhibited, the protective effect of Emodin was eliminated. Inhibiting Akt also reduced the level of HO-1. In cell experiments, Emodin reduced inflammation and apoptosis in the OGD/R cell model. Additionally, when Akt or HO-1 was inhibited, the protective effect of Emodin was weakened.Conclusions: Our findings suggest that Emodin may protect the intestine against II/R injury through the Akt/HO-1 signaling pathway.


  • Emodin alleviates intestinal ischemia/reperfusion-induced lung injury by upregulating HO-1 expression via PI3K/AkT pathway

    by Meng Chen, Tuo Ji, Yin-Yin Liu, Wan-Li Liu, Xue-Tao Yan, Hai-Xing Jiang, Zong-Ze Zhang, Xiang-Hu He


  • Open Access

    Crtc1 deficiency protects against sepsis-associated acute lung injury through activating akt signaling pathway

    by Meng Chen, Jian Lv, Ningning Guo, Tuo Ji, Yu Fang, Zhihua Wang, Xianghu He

    Interplay between systemic inflammation and programmed cell death contributes to the pathogenesis of acute lung injury (ALI). cAMP-regulated transcriptional coactivator 1 (CRTC1) has been involved in the normal function of the pulmonary system, but its role in ALI remains unclear. We generated a Crtc1 knockout (KO; Crtc1−/−) mouse line. Sepsis-induced ALI was established by cecal ligation and puncture (CLP) for 24 h. The data showed that Ctrc1 KO substantially ameliorated CLP-induced ALI phenotypes, including improved lung structure destruction, reduced pulmonary vascular permeability, diminished levels of proinflammatory cytokines and chemokines, compared with the wildtype mice. Consistently, in lipopolysaccharide (LPS)-treated RAW264.7 cells, Crtc1 knockdown significantly inhibited the expression of inflammatory effectors, including TNF-α, IL-1β, IL-6 and CXCL1, whereas their expressions were significantly enhanced by Crtc1 overexpression. Moreover, both Crtc1 KO in mice and its knockdown in RAW264.7 cells dramatically reduced TUNEL-positive cells and the expression of pro-apoptotic proteins. In contrast, Crtc1 overexpression led to an increase in the pro-apoptotic proteins and LPS-induced TUNEL-positive cells. Mechanically, we found that the phosphorylation of Akt was significantly enhanced by Crtc1 knockout or knockdown, but suppressed by Crtc1 overexpression. Administration of Triciribine, an Akt inhibitor, substantially blocked the protection of Crtc1 knockdown on LPS-induced inflammation and cell death in RAW264.7 cells. Our study demonstrates that CRTC1 contribute to the pathological processes of inflammation and apoptosis in sepsis-induced ALI, and provides mechanistic insights into the molecular function of CRTC1 in the lung. Targeting CRTC1 would be a promising strategy to treat sepsis-induced ALI in clinic.

  • Open Access

    Dexmedetomidine Ameliorates Lung Injury Induced by Intestinal Ischemia/Reperfusion by Upregulating Cannabinoid Receptor 2, Followed by the Activation of the Phosphatidylinositol 3-Kinase/Akt Pathway

    by Meng Chen, Xue-Tao Yan, Li Ye, Jun-Jiao Tang, Zong-Ze Zhang, Xiang-Hu He

    Intestinal ischemia/reperfusion (I/R) is a clinical emergency, which often causes lung injury with high morbidity and mortality. Although dexmedetomidine has been identified to have a protective effect on lung injury caused by intestinal I/R, its specific mechanism is still elucidated. In recent years, the cannabinoid (CB2) receptor pathway has been found to be involved in I/R injury of some organs. In the current study, we investigated whether the CB2receptor pathway contributes to the protective effect of dexmedetomidine on the intestinal I/R-induced lung injury in rats. Dexmedetomidine treatment upregulated the expression of CB2receptor and suppressed the I/R-induced increases in lung injury scores, inflammatory cell infiltration, lung wet/dry ratio, MPO activity, MDA level, inflammatory cytokines, and caspase-3 expression while augmenting SOD activity and Bcl-2 expression, indicating attenuation of lung injury. Dexmedetomidine treatment also increased the expression of Akt. The protective effects of dexmedetomidine treatment were reversed by the CB2receptor antagonist AM630 or the PI3K inhibitor wortmannin. And the CB2receptor antagonist AM630 also downregulated the expression of Akt. Thus, our findings suggest that treatment with dexmedetomidine provides a protective role against lung injury caused by intestinal I/R in rats, possibly due to the upregulation of the CB2receptor, followed by the activation of the PI3K/Akt pathway.


  • SP1, MYC, CTNNB1, CREB1, JUN genes as potential therapy targets for neuropathic pain of brain

    by Xue‐Tao Yan, Yong Xu, Xiao‐Li Cheng, Xiang‐Hu He, Yu Wang, Wen‐Zhong Zheng, Ying Zhao, Hu Chen, Yan‐Lin Wang

    Neuropathic pain (NP) may cause serious brain diseases, but the genes associated with the metabolic pathway and transcript factors of NP remain unclear. This study is aimed to identify the therapy target genes for NP and to investigate the metabolic pathways and transcript factors associated with NP. The differentially expressed genes of three brain tissues (nucleus accumbens, periaqueductal gray, and prefrontal cortex) dealt with NP stimulation were analyzed. Besides, The Database for Annotation, Visualization, and Integrated Discovery and Tfacts datasets were used in the analysis of the genes related to the metabolic pathway and transcript factors of the brain. Eight genes were found to coexpress in all three tissues. A functional enrichment analysis showed that the upregulated genes were mostly enriched in pathways as inflammatory response, calcium‐mediated signaling, cytokine‐cytokine receptor interaction, and extracellular matrix (ECM)‐receptor interaction, whereas the downregulated genes were mostly enriched in pathways as phospholipid metabolic processes, positive regulation of protein kinase B signaling, and metabolism of xenobiotics by cytochrome P450. Finally, 135 and 98 transcript factors genes were upregulated and downregulated, among which SP1, MYC, CTNNB1, CREB1, JUN were identified as the most critical genes because the number of up‐ and downregulated gene ranked at the top. In conclusion, the pathways of immune response and cytokine‐cytokine receptor interaction were determined as the main metabolic pathways of NP affecting the brain, and SP1, MYC, CTNNB1, CREB1, JUN genes were recognized as the most enriched genes in this process, which may provide evidence for the diagnosis and treatment research of neuropathic pain.


  • XIST accelerates neuropathic pain progression through regulation of miR‐150 and ZEB1 in CCI rat models

    by Xue‐Tao Yan, Jing‐Min Lu, Yu Wang, Xiao‐Li Cheng, Xiang‐Hu He, Wen‐Zhong Zheng, Hu Chen, Yan‐Lin Wang

    LncRNAs are reported to participate in neuropathic pain development. LncRNA X‐inactive specific transcript (XIST) is involved in the progression of various cancers. However, the role of XIST in neuropathic pain remains unclear. In our present study, we established a chronic constriction injury (CCI) rat model and XIST was found to be greatly upregulated both in the spinal cord tissues and in the isolated microglias of CCI rats. Inhibition of XIST inhibited neuropathic pain behaviors including mechanical and thermal hyperalgesia. Moreover, decrease of XIST repressed neuroinflammation through inhibiting COX‐2, tumor necrosis factor (TNF)‐α and IL‐6 and in CCI rats. Previously, miR‐150 has been reported to restrain neuropathic pain by targeting TLR5. Currently, miR‐150 was predicted to be a microRNA target of XIST, which indicated a negative correlation between miR‐150 and XIST. miR‐150 was remarkably decreased in CCI rats and overexpression of miR‐150 can significantly suppress neuroinflammation‐related cytokines. Furthermore, ZEB1 was exhibited to be a direct target of miR‐150 and we found it was overexpressed in CCI rats. Silencing ZEB1 was able to inhibit neuropathic pain in vivo and downreguation of XIST decreased ZEB1, which can be reversed by miR‐150 inhibitors. Taken these together, we indicated that XIST can induce neuropathic pain development in CCI rats via upregulating ZEB1 by acting as a sponge of miR‐150. It was revealed that XIST/miR‐150/ZEB1 axis can be provided as a therapeutic target in neuropathic pain.


  • Open Access

    Transduced PEP‐1‐Heme Oxygenase‐1 Fusion Protein Attenuates Lung Injury in Septic Shock Rats

    by Xue-Tao Yan, Xiang-Hu He, Yan-Lin Wang, Zong-Ze Zhang, Jun-Jiao Tang

    Oxidative stress and inflammation have been identified to play a vital role in the pathogenesis of lung injury induced by septic shock. Heme oxygenase‐1 (HO‐1), an effective antioxidant and anti‐inflammatory and antiapoptotic substance, has been used for the treatment of heart, lung, and liver diseases. Thus, we postulated that administration of exogenous HO‐1 protein transduced by cell‐penetrating peptide PEP‐1 has a protective role against septic shock‐induced lung injury. Septic shock produced by cecal ligation and puncture caused severe lung damage, manifested in the increase in the lung wet/dry ratio, oxidative stress, inflammation, and apoptosis. However, these changes were reversed by treatment with the PEP‐1‐HO‐1 fusion protein, whereas lung injury in septic shock rats was alleviated. Furthermore, the septic shock upregulated the expression of Toll‐like receptor 4 (TLR4) and transcription factor NF‐κB, accompanied by the increase of lung injury. Administration of PEP‐1‐HO‐1 fusion protein reversed septic shock‐induced lung injury by downregulating the expression of TLR4 and NF‐κB. Our study indicates that treatment with HO‐1 protein transduced by PEP‐1 confers protection against septic shock‐induced lung injury by its antioxidant, anti‐inflammatory, and antiapoptotic effects.


  • Inhibition of miR‐200b/miR‐429 contributes to neuropathic pain development through targeting zinc finger E box binding protein‐1

    by Xue‐Tao Yan, Ying Zhao, Xiao‐Li Cheng, Xiang‐Hu He, Yu Wang, Wen‐Zhong Zheng, Hu Chen, Yan‐Lin Wang

    Many studies have reported that microRNAs participate in neuropathic pain development. Previously, miR‐200b and miR‐429 are reported to be involved in various diseases. In our current study, we focused on their roles in neuropathic pain and we found that miR‐200b and miR‐429 were significantly decreased in chronic constriction injury (CCI) rat spinal cords and isolated microglials. miR‐200b and miR‐429 overexpression were able to relieve neuropathic pain through modulating PWT and PWL in CCI rats. Meanwhile, we observed that both miR‐200b and miR‐429 upregulation could repress neuroinflammation via inhibiting inflammatory cytokines such as IL‐6, IL‐1β, and TNF‐α in CCI rats. By carry out bioinformatics technology, Zinc finger E box binding protein‐1 (ZEB1) was predicted as target of miR‐200b, and miR‐429 and dual‐luciferase reporter assays confirmed the correlation between them. ZEB1 has been reported to regulate a lot of diseases. Here, we found that ZEB1 was greatly increased in CCI rats and miR‐200b and miR‐429 overexpression markedly suppressed ZEB1 mRNA expression in rat microglial cells. In addition, knockdown of ZEB1 can reduce neuropathic pain development and co‐transfection of LV‐anti‐miR‐200b/miR‐429 reversed this phenomenon in vivo. Taken these together, our results suggested that miR‐200b/miR‐429 can serve as an important regulator of neuropathic pain development by targeting ZEB1.